Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LongBio's LP-003 Achieves Its Fourth IND Approval
Details : LP-003 is the company's next-generation anti-IgE antibody. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of food allergy.
Brand Name : LP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 25, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Qiming Venture Partners
Deal Size : $1.4 million
Deal Type : Series B Financing
LongBio Announced the Completion of Series B2 Financing, Led by Qiming Venture Partners
Details : The financing aims to advance the clinical development of the company's lead product LP-003, a best-in-class, anti-IgE antibody, which is being evaluated for Chronic Spontaneous Urticaria.
Brand Name : LP-003
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Qiming Venture Partners
Deal Size : $1.4 million
Deal Type : Series B Financing
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD
Details : LP-003 is a novel humanized monoclonal anti-IgE antibody candidate, which is being evaluated for the treatment of patients with chronic spontaneous urticaria.
Brand Name : LP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 12, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
Details : LP-003 is a novel monoclonal anti-IgE antibody, which is currently being evaluated for the treatment of adults with moderate-to-severe chronic spontaneous urticaria.
Brand Name : LP-003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 25, 2024
Lead Product(s) : LP-003
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?